logo-loader

Mydecine - Mental health solutions advancing

Last updated: 11:59 20 Dec 2021 EST, First published: 10:59 20 Dec 2021 EST

Mydecine Innovations Group is a biotech and life sciences company developing and commercialising new therapies for mental health and other conditions. In recent months the company has achieved further progress in maturing its intellectual property (IP) portfolio and adding new proprietary compounds. We present a brief review of the main developments:

The most important feature, in our view, has been the further advancement of Mydecine’s programme with drugs derived from the psychedelic compound psilocybin for application in smoking cessation therapies. During the third quarter (Q3) the company announced a five-year research agreement with Johns Hopkins University School of Medicine, covering nicotine addiction and other indications. Also in conjunction with Johns Hopkins, the company expects to launch a seamless Phase 2/3 clinical trial for smoking cessation in Q1 2022 led by Dr Matthew Johnson, using Mydecine’s proprietary MYCO-001 formulation from psilocybin. Dr Johnson will also launch a multi-site NIDA (National Institute on Drug Abuse) grant-funded smoking cessation study using MYCO-001, which represents the first time in over 50 years that the US government has funded a study using a psychedelic compound for therapeutics.

 

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities,...

FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:

This document is published by Proactive Research and its contents have not been approved as a financial promotion by Proactive Investors Limited or any other FCA authorised person. This communication is made on the basis of the 'journalist exemption' provide for in Article 20 of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and having regard to the FCA rules, and in particular PERG 8.12.

Where the note contains a ‘buy, sell, hold’ recommend, Proactive Investors Limited is authorised to provide investment advice as defined by Article 53 of the RAO

FOR OUR FULL DISCLAIMER CLICK HERE

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

1 hour, 35 minutes ago